Bevacizumab,Durvalumab,Olaparib,Carboplatin,Paclitaxel
AstraZeneca,roche,Merck
['olaparib', 'durva', 'ovarian', 'brca']
results show that durvalumab plus olaparib added to standard care improves pfs in newly diagnosed advanced #ovariancancer w/out brca mutation. findings were introduced in an #asco23 news briefing. of shares insights. #onctwitter 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.